-

Viz.ai Launches Viz ACS™ to Accelerate Treatment for Heart Attack and Reduce Unnecessary Activations

New solution helps reduce false activations through real-time data sharing and team coordination

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz ACS, a new solution in the Viz Cardio™ Suite. Designed to unite the acute coronary syndrome (ACS) care team on a single platform, Viz ACS provides Emergency Department (ED) physicians and cardiologists with the same high-quality ECGs and patient data in real time. This streamlined workflow can help improve communication, speeds treatment, and reduces unnecessary cath lab activations.

“Viz ACS gives immediate access to ambulance and ED ECGs all in one place,” said Dr. Gregory Means, a practicing interventional cardiologist. “Instead of blurry text messages, I can coordinate with EMS, ED, and cath lab teams in a HIPAA-compliant environment, and activate the cath lab only when needed. This saves time, avoids false alarms, and ensures patients are ready for percutaneous coronary intervention (PCI) as soon as they arrive.”

Viz ACS consolidates ECGs from the ambulance, emergency department, and prior encounters into a HIPAA-compliant mobile viewer, giving cardiologists immediate access to a patient’s full history to track serial changes and interpret the latest ECG in context. When a heart attack is suspected, ED teams can escalate directly to the on-call interventional cardiologist, who can review ECGs and patient data in real time and activate the cath lab with a single click. This secure, streamlined workflow replaces screenshots and fragmented text chains with improved coordination across the care team.

“From our earliest work in stroke, Viz has focused on harnessing technology to give physicians the tools they need to act faster and coordinate care when every second counts,” said Dr. Andrew M. Ibrahim, MD, MSc, chief clinical officer at Viz.ai. “With Viz ACS, we’re expanding that commitment into cardiology, bringing the same proven approach to acute cardiac conditions where speed is critical. The addition of ACS is another step toward our vision of an enterprise-wide solution that spans specialties—making it easier for health systems to care for every patient, in every corner of healthcare.”

Viz ACS builds on Viz.ai’s leadership in acute care coordination and significantly advances Viz’s mission to increase access to life-saving treatments. In 2025, Viz.ai was ranked the #1 AI-Powered Acute Care Platform by hospitals and health systems in the Black Book™ Research survey, leading in 11 key performance indicators—more than any other vendor—underscoring its unmatched effectiveness in acute care workflows.

To learn more about Viz ACS, visit viz.ai/viz-acs.

About Viz.ai

Viz.ai is the leader in AI-powered care coordination and clinical workflow solutions, deployed in over 1,800 hospitals across the U.S. and trusted by most of the top life sciences companies. Its platform uses artificial intelligence to detect diseases earlier, synchronize care teams, and ensure patients get to the right treatment faster. Viz.ai was the first company awarded CMS reimbursement for AI and ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey, setting the standard for innovation in healthcare. For more information visit Viz.ai.

Contacts

Media Contact
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger / Daniel Hoadley
daniel.yunger@kekstcnc.com / daniel.hoadley@kekstcnc.com

Viz.ai


Release Versions

Contacts

Media Contact
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger / Daniel Hoadley
daniel.yunger@kekstcnc.com / daniel.hoadley@kekstcnc.com

Social Media Profiles
More News From Viz.ai

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...

Viz.ai Launches Viz Assist: The First Multimodal AI Agent Platform for Faster Treatment and Better Outcomes

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz Assist™, a suite of autonomous AI agents that significantly enhance how care teams identify, prioritize, and act on critical patient data.1 Viz Assist marks a major step forward in Viz.ai’s mission to use technology to reduce time to treatment and improve patient outcomes. Viz Assist incorporates inputs from ambient listening and the electronic...

Viz.ai Appoints Dr. Andrew M. Ibrahim as Chief Clinical Officer to Advance AI-Powered Healthcare

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the appointment of Andrew M. Ibrahim, MD, MSc as its new Chief Clinical Officer (CCO). Dr. Ibrahim will lead Viz.ai’s clinical strategy and oversee the integration of generative artificial intelligence into healthcare delivery to improve quality, efficiency, and patient outcomes. He will report to Chris Mansi, MD, CEO and co-founder of Viz.ai. Dr. Ibrahim is a bo...
Back to Newsroom